One US-made drug treats congenital syphilis, and the country is running short

The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis. Pfizer's recall of the drug due to contamination risks, combined with limited manufacturing capacity, has delayed supply until 2027, raising concerns about rising infection rates and disparities affecting Indigenous and Black infants.